CREDIT: CC0 PUBLIC DOMAIN
Two doses of A Simple Tuberculosis Vaccination After Surgery Helps The Imamune System Fight Cancer Cells and Could Greatly Improve Patcomes for the Most Common Type of Bladder Cancer, According to a Pilot Study of 40 Patients.
Initial Results from the Ruitivec-1 Trial Were Gifted at the European Association of Urology (EAU) Congress In Madrid.
In the Randomized Controlled Trial, Administering the Vaccine Alongside Standard Treatment Led to An Elevated Imamune Response, Which is Known to Improve the Body’s Ability to Suppress Future Tumors. Patients Who Received The Vaccine Had No Discernible Side Effects and Every Patient Was Cancer-free Five Years.
BLADDER CANCER IS THE NINTH MOST COMMON CANCER IN THE WORLD, WITH OVER 600.000 PEOPLE DIAGNOSED IN 2022. NON-MUSCLE INVASIVE BLADDER CANCER IS AN EARLY-STAGE CANCER THAT AFFECTS THE LINING OF THE BLADDER AND HAS NOT PROGRESSED INTO THE DEEPER MUSCLE LAYER.
Following Surgery to remove the tumor, Bladder Cancer Patients Are Typially Given a Live Bacilus Calmette Guerin (BCG) Inoculation Directly into the Bladder to Help Immune System Destroy Any Remaining Cancer Cells. WHILE THIS REDUCES THE CHANCE OF THEIR CANCER COMING BACK, UP TO 50% OF PATIES GO ON TO EXPERIENCE RECURUTENCE OR PROGRESSION.
Main Investigator, Dr. Cecilia Cabrera, of Irhica and IGTP, Barcelona, and Colleagues Tested whether an Addihthe Injection of a Non-Live Tb Vaccine, Called Ruti, Wold Further Boost Patients’ Imamune Response In A Small Pilot Study.
They found that the ruti vaccine significantly enhanced the bcg-innduced imamune response compared with the control group. RUTI VACCINATION WAS ALSO ASSOCIATED WITH SIGNENTLY HIGHER PROGRESSION-FREE SURVIVAL, WITH EVERY PATT IN THE RUTI GROUP TUMOR-FEE FIVES LATER COMPARED WITH 13 OF 18 PATENTS IN THE CONTROL GROUP.
Dr. Cabrera says, “We Expected That the Ruti Vaccine Would Impall The Imamune Response for Patients, But We Didn’t Know What Effect This Might have on Cancer Progression Over Five Years. It was very very surprising for us to see Such a Vast Improvement Even Even with Such a Small Group of Patients. “
RUTI VACCINATION WAS ALSO WELL TOLERATED BY PAIENTS, WITH ONLY A MILD REACTION AT THE INJECTION SITE AND IN SYSTEMIC ADVERSE EFFECTS.
Dr. Cabrera says, “This Was a Small Pilot Study, But We’ve Been Really Encouraged by the Reduction in Disease Recurence and Progression in Patients Treated with the Ruti Vaccine.
“We Were Particularly Pleased to See ThatSe Results are Further Supported by an Exploratory Sub-Aalysis Including Only High-Grade T1 Bladder Cancer Patients. With Such High Rates of Recurence in Bladder Cancer, Finding New Ways To Prevent This is very important.”
Ruti is Being Developed as a therapeutic vaccine againt tuberculosis by Archivel Farma sl. In Parallel, Ruti is Being Developed as an immunotherapeutic agent for Bladder Cancer as a collaboration Between Irisica, IGTP and Archivel Farma.
Joost Boormans, Professor of Urology at the Erasmus University Medical Center, The Netherlands, and A Member of the Eau Scientific Congress Office, Said, “This is a well-Conducted Pilot Study and Promising Results.
“With Just Two Injections Over and Above Standard Treatment, The Burden On Patients Is Very Small and I Look Forward to Seeing Whether Further Studies in Larger Cohorts Continue To Demonstrate The Benefits to Patients and Improve Their Outcomes.”
The Researchers Caution That a Larger Trial Will Be Needed to Confirm the Results Before The Treatment Can Be Considered For Wider Use.
Citation: Second tb Vaccination Boosts immunity in Bladder Cancer Patients and Reduces Cancer Recurence, Pilot Study Suggesss (2025, March 22) Retrieved 23 March 2025 from
This document is Subject to Copyright. Apart from Any Fair Dealing for the Purpose of Private Study or Research at Part May Be Reproduced Without The Written Permission. The Content is Provided for Information Purposes Only.
